[go: up one dir, main page]

NO20200671A1 - Sammensetninger og fremgangsmåter for modulering av hemostase - Google Patents

Sammensetninger og fremgangsmåter for modulering av hemostase

Info

Publication number
NO20200671A1
NO20200671A1 NO20200671A NO20200671A NO20200671A1 NO 20200671 A1 NO20200671 A1 NO 20200671A1 NO 20200671 A NO20200671 A NO 20200671A NO 20200671 A NO20200671 A NO 20200671A NO 20200671 A1 NO20200671 A1 NO 20200671A1
Authority
NO
Norway
Prior art keywords
compositions
methods
modulating hemostasis
hemostasis
modulating
Prior art date
Application number
NO20200671A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20200671A1 publication Critical patent/NO20200671A1/no
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20200671A 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase NO20200671A1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (1)

Publication Number Publication Date
NO20200671A1 true NO20200671A1 (no) 2008-07-30

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20082182A NO345177B1 (no) 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200671A NO20200671A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200670A NO20200670A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20082182A NO345177B1 (no) 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20200670A NO20200670A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Country Status (26)

Country Link
US (4) US8383386B2 (no)
EP (4) EP1948690B1 (no)
JP (4) JP5823088B2 (no)
KR (4) KR101827569B1 (no)
CN (1) CN101356192B (no)
AU (1) AU2006315175B2 (no)
BR (1) BRPI0618654B1 (no)
CA (2) CA2629491C (no)
CR (1) CR9956A (no)
DK (1) DK1948690T3 (no)
EC (1) ECSP088452A (no)
ES (2) ES2549929T3 (no)
GT (1) GT200800065A (no)
HK (2) HK1128699A1 (no)
IL (1) IL191310A (no)
MX (3) MX2008006313A (no)
MY (1) MY162181A (no)
NO (3) NO345177B1 (no)
NZ (1) NZ568108A (no)
PL (1) PL1948690T3 (no)
PT (1) PT1948690E (no)
RU (2) RU2008123398A (no)
SI (1) SI1948690T1 (no)
SV (1) SV2008002906A (no)
WO (1) WO2007059513A2 (no)
ZA (1) ZA200804026B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2193196B1 (en) 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
PT2414517T (pt) 2009-03-30 2016-12-27 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
AU2014210830A1 (en) 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
CA2928762A1 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
ES2772802T3 (es) * 2014-01-24 2020-07-08 Pfizer Composiciones y procedimientos para tratar la hemorragia intracerebral
US10537618B2 (en) * 2014-05-26 2020-01-21 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
US11708570B2 (en) 2016-07-27 2023-07-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating Factor IX function
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8436144B2 (en) * 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
CR9956A (es) 2008-08-21
KR20080078664A (ko) 2008-08-27
BRPI0618654A2 (pt) 2011-09-06
NO345177B1 (no) 2020-10-26
US20180251745A1 (en) 2018-09-06
KR20140005383A (ko) 2014-01-14
NO20082182L (no) 2008-07-30
US20090175931A1 (en) 2009-07-09
RU2570547C2 (ru) 2015-12-10
ES2496567T3 (es) 2014-09-19
ES2549929T3 (es) 2015-11-03
AU2006315175A1 (en) 2007-05-24
EP2431390A1 (en) 2012-03-21
IL191310A (en) 2015-06-30
MY162181A (en) 2017-05-31
JP2014073127A (ja) 2014-04-24
KR101600158B1 (ko) 2016-03-08
SI1948690T1 (sl) 2014-09-30
EP2423224B1 (en) 2015-08-12
EP1948690A2 (en) 2008-07-30
JP5957167B2 (ja) 2016-07-27
CA2629491C (en) 2019-05-07
NZ568108A (en) 2011-09-30
EP2431389A1 (en) 2012-03-21
MX336958B (es) 2016-02-05
CN101356192A (zh) 2009-01-28
RU2011130932A (ru) 2013-01-27
CA2971971A1 (en) 2007-05-24
HK1165444A1 (zh) 2012-10-05
JP6571735B2 (ja) 2019-09-04
JP2009515559A (ja) 2009-04-16
KR20160029135A (ko) 2016-03-14
HK1128699A1 (en) 2009-11-06
MX337059B (es) 2016-02-09
SV2008002906A (es) 2008-10-22
RU2008123398A (ru) 2009-12-27
KR101827569B1 (ko) 2018-02-09
PL1948690T3 (pl) 2014-11-28
MX2008006313A (es) 2008-11-06
US20160362673A1 (en) 2016-12-15
JP5823088B2 (ja) 2015-11-25
CN101356192B (zh) 2013-09-11
NO20200670A1 (no) 2008-07-30
WO2007059513A3 (en) 2007-11-29
US9896676B2 (en) 2018-02-20
GT200800065A (es) 2008-11-03
BRPI0618654B1 (pt) 2021-10-19
EP2423224A1 (en) 2012-02-29
JP2018033459A (ja) 2018-03-08
ZA200804026B (en) 2009-10-28
JP6236194B2 (ja) 2017-11-22
EP1948690B1 (en) 2014-06-11
EP1948690A4 (en) 2009-06-17
US20140120155A1 (en) 2014-05-01
US9410137B2 (en) 2016-08-09
JP2016005464A (ja) 2016-01-14
KR101574042B1 (ko) 2015-12-03
US8383386B2 (en) 2013-02-26
BRPI0618654A8 (pt) 2019-01-15
AU2006315175B2 (en) 2013-02-07
DK1948690T3 (da) 2014-09-01
CA2629491A1 (en) 2007-05-24
EP2431390B1 (en) 2015-08-12
PT1948690E (pt) 2014-09-08
WO2007059513A2 (en) 2007-05-24
KR20140115374A (ko) 2014-09-30
ECSP088452A (es) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20200670A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
LTPA2017037I1 (lt) Kompozicijos ir būdai, skirti SMN2 splaisingo moduliavimui
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1858488T4 (da) Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
EP1940423A4 (en) METHODS AND COMPOSITIONS OF TISSUE GENIUS
IL194788A0 (en) Compositions and methods for modulating vascular development
EP1896050A4 (en) LKKTET AND / OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK2063907T3 (da) Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
DK1891208T3 (da) Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf
DK2089047T3 (da) Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
IL185753A0 (en) Methods and compositions for modulating vascular integrity
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
EP1763358A4 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING THE APPETITE
DK1846531T3 (da) Spotting-fluidumsammensætninger og dertil hørende fremgangsmåder
DK2114424T3 (da) Betalain-faststofsammensætninger og fremgangsmåder
EP1809761A4 (en) COMPOSITIONS AND METHOD FOR MODULATING DHR96
AU2005905891A0 (en) Methods and compositions for modulating TBF-Beta and collagen
ITPD20050090U1 (it) Attrezzatura spaccalegna
FIU20050108U0 (fi) Halkaisulaite
ATE548575T1 (de) Gleichlaufscheibegelenk